Pharvaris N.V. PHVS
Updated: 16 Jun 2026
No signal published yet
We already track Pharvaris N.V. and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Pharvaris N.V.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Pharvaris N.V. free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
In June 2026, Pharvaris presented detailed Phase 3 RAPIDe-3 and long-term CHAPTER-1 data for deucrictibant at the EAACI 2026 Congress, showing a favorable safety profile and high efficacy. The company also announced its Annual General Meeting for June 26, 2026, following a $132 million share offering in May 2026.
What Firelda Watch includes for Pharvaris N.V.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Pharvaris N.V.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Pharvaris N.V. free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more